5 Analysts Assess Adaptive Biotechnologies: What You Need To Know
Earnings Call Summary | Recursion Pharmaceuticals(RXRX.US) Q1 2025 Earnings Conference
Recursion Pharmaceuticals Outlines Focused R&D Pipeline With Multiple Catalysts Through 2026
Earnings Call Summary | Twist Bioscience(TWST.US) Q2 2025 Earnings Conference
Twist Bioscience Outlines Adjusted EBITDA Breakeven by Fiscal 2026 With Revenue Growth Targets
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $9
Guardant Health Analyst Ratings
Tempus AI Launches Notetaker, AI-Powered Clinical Assistant To Aid Psychiatrists In Generating Progress Note
Recursion Pharmaceuticals Shares Are Trading Lower After the Company Reported Mixed Q1 Financial Results.
Netflix, CNA Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Twist Bioscience GAAP EPS of -$0.66 Misses by $0.12, Revenue of $92.79M Beats by $0.75M
Earnings Scheduled For May 5, 2025
Reported Sunday, Recursion's REC-4881 Shows 43% Median Polyp Reduction In Phase 1b/2 FAP Study At Week 13 Assessment
Here's the Major Earnings Before the Open Tomorrow
SA Asks: What Are the Best Quantum Computing Stocks?
What's Next: Twist Bioscience's Earnings Preview
Catalyst Watch: Powell Presser, AMD Earnings, IBM Event, and Lions Gate Splits in Two
Nasdaq Surges Over 300 Points; Apple Shares Fall After Q2 Results
Recursion Pharmaceuticals Q1 2025 Earnings Preview
12 Health Care Stocks Moving In Friday's Intraday Session